Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983;15(Suppl 1):31S–37S. doi: 10.1111/j.1365-2125.1983.tb02104.x

Human blood platelet behaviour after inhibition of thromboxane synthetase

S Heptinstall, Susan C Fox
PMCID: PMC1427694  PMID: 6401998

Abstract

1 We have determined the extent to which sodium arachidonate (NaAA) induces a release reaction in platelet-rich plasma (PRP) from different individuals and have studied the ability of the thromboxane synthetase inhibitor UK 34787 to modify this release. We have also determined the extent of the platelet release reaction induced in PRP from different individuals by preparations of platelet-derived thromboxane A2 (TXA2).

2 The release of [14C]-serotonin induced by NaAA is more extensive in PRP from some individuals than from others.

3 There is a direct relation between the extent of the release reaction induced in different PRPs by NaAA and TXA2.

4 UK 34787 prevents the NaAA-induced release reaction in PRP from some individuals (“responders”) but not in PRP from others (“non-responders”).

5 The mean extent of the NaAA-induced release reaction for the “non-responders” was significantly higher than that for the “responders” even in the absence of UK 34787, but there was some overlap between the individual results.

6 Platelets from “responders” and “non-responders” did not differ in the amount of malondialdehyde (MDA) produced or in the effectiveness with which UK 34787 inhibited MDA production.

7 Platelet-derived TXA2 from “responders” and “non-responders” did not have markedly different effects when tested in a single preparation of PRP.

Full text

PDF
31S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartele V., Cerletti C., Schiepatti A., di Minno G., de Gaetano G. Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet. 1981 May 9;1(8228):1057–1058. doi: 10.1016/s0140-6736(81)92224-8. [DOI] [PubMed] [Google Scholar]
  2. Butler K. D., Maguire E. D., Smith J. R., Turnbull A. A., Wallis R. B., White A. M. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation. Thromb Haemost. 1982 Feb 26;47(1):46–49. [PubMed] [Google Scholar]
  3. Cockbill S. R., Heptinstall S., Taylor P. M. A comparison of the abilities of acetylsalicylic acid, flurbiprofen and indomethacin to inhibit the release reaction and prostaglandin synthesis in human blood platelets. Br J Pharmacol. 1979 Sep;67(1):73–78. [PMC free article] [PubMed] [Google Scholar]
  4. Cross P. E., Dickinson R. P., Parry M. J., Randall M. J. 3-(1-imidazolylmethyl) indoles: potent and selective inhibitors of human blood platelet thromboxane synthetase. Agents Actions. 1981 May;11(3):274–280. doi: 10.1007/BF01967626. [DOI] [PubMed] [Google Scholar]
  5. Di Minno G., Silver M. J., de Gaetano G. Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol. 1979 Dec;43(4):637–647. doi: 10.1111/j.1365-2141.1979.tb03797.x. [DOI] [PubMed] [Google Scholar]
  6. Grimm L. J., Knapp D. R., Senator D., Halushka P. V. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res. 1981 Nov 15;24(4):307–317. doi: 10.1016/0049-3848(81)90004-9. [DOI] [PubMed] [Google Scholar]
  7. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A. 1974 Feb;71(2):345–349. doi: 10.1073/pnas.71.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heptinstall S., Bevan J., Cockbill S. R., Hanley S. P., Parry M. J. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res. 1980 Oct 15;20(2):219–230. doi: 10.1016/0049-3848(80)90387-4. [DOI] [PubMed] [Google Scholar]
  10. O'Brien J. R. Effects of salicylates on human platelets. Lancet. 1968 Apr 13;1(7546):779–783. doi: 10.1016/s0140-6736(68)92228-9. [DOI] [PubMed] [Google Scholar]
  11. O'Brien J. R., Finch W., Clark E. A comparison of an effect of different anti-inflammatory drugs on human platelets. J Clin Pathol. 1970 Sep;23(6):522–525. doi: 10.1136/jcp.23.6.522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Vermylen J., Defreyn G., Carreras L. O., Machin S. J., Van Schaeren J., Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet. 1981 May 16;1(8229):1073–1075. doi: 10.1016/s0140-6736(81)92241-8. [DOI] [PubMed] [Google Scholar]
  13. Weiss H. J., Aledort L. M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968 Sep;47(9):2169–2180. doi: 10.1172/JCI105903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zucker M. B., Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med. 1968 Feb;127(2):547–551. doi: 10.3181/00379727-127-32737. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES